keyword
MENU ▼
Read by QxMD icon Read
search

I-131

keyword
https://www.readbyqxmd.com/read/27882089/gender-impact-on-the-correlation-between-thyroid-function-and-serum-lipids-in-patients-with-differentiated-thyroid-cancer
#1
Xue Li, Zhaowei Meng, Jian Tan, Ming Liu, Qiang Jia, Guizhi Zhang, Yajing He, Qing Zhang, Li Liu, Kun Song, Qing He, Mei Zhu, Shen Wang, Jianping Zhang, Wei Zheng, Renfei Wang, Tianpeng Hu, Na Liu, Arun Upadhyaya
The present study aimed to explore the association between thyroid stimulating hormone (TSH) and serum lipids in patients with differentiated thyroid cancer (DTC), with a focus on the risk of hyperlipidemia between different genders. The study included 352 DTC patients who were ready to receive I-131 therapy as well as 352 matched normal controls. In the DTC group, 157 patients were monitored for TSH and lipid parameters prior to and after 1 month of thyroxine therapy. Results were analyzed using t-tests, Pearson bivariate correlation and binary logistic regression analyses...
November 2016: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/27831763/thyroid-patient-salivary-radioiodine-transit-and-dysfunction-assessment-using-chewing-gums
#2
Demetrios Okkalides
Radiation-induced salivary gland dysfunction is the most frequent side-effect of I-131 thyroid therapy. Here, a novel saliva sampling method with ordinary chewing gums administered to the patients at appropriate time intervals post-treatment (TIPT) was used to relate this effect to chewing gum saliva activity (CGSA) content. Saliva samples were acquired after the oral administration of prescribed I-131 activity (radioactivity administered [RA]) to 19 differentiated thyroid cancer (DTC) and 16 hyperthyroidism patients of the radioisotope unit (RIU) during 2014 and 2015...
November 2016: Cancer Biotherapy & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27824959/risk-factors-and-stratification-for-recurrence-of-patients-with-differentiated-thyroid-cancer-elevated-thyroglobulin-and-negative-i-131-whole-body-scan-by-restaging-18-f-fdg-pet-ct
#3
Kursat Okuyucu, Semra Ince, Engin Alagoz, Ozdes Emer, Huseyin San, Elif Balkan, Aslı Ayan, Coskun Meric, Cem Haymana, Cengizhan Acıkel, Bengul Gunalp, Alper Ozgur Karacalioglu, Nuri Arslan
OBJECTIVE: In nearly 20%-30% of patients with differentiated thyroid carcinoma (DTC) relapse and 7% of them die during the next 10 years after initial diagnosis. In 10%-30% of patients with DTC after ablation therapy during the follow-up show a negative iodine-131 ((131)I) whole-body screening test ((131)I WBS) and increased serum thyroglobulin (Tg) level. Loss of ability of DTC metastatic lesions to trap (131)I is associated with pure survival and often aggressive disease. Several studies have shown that in DTC cases non trapping (131)I, fluorine-18-fluorodeoxyglucose positron emission tomography ((18)F-FDG PET) can detect recurrence or metastases with high sensitivity (80%-90%)...
November 8, 2016: Hellenic Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/27813128/preparation-and-preclinical-evaluation-of-131-i-trastuzumab-for-breast-cancer
#4
Mythili Kameswaran, Vikram Gota, Rajwardhan Ambade, Sudeep Gupta, Ashutosh Dash
Trastuzumab that targets the human epidermal growth factor receptor type 2 (HER2) is known to benefit patients with HER2+ metastatic breast cancer. The objective was to explore the potential of (131) I-trastuzumab for treatment of breast cancers. Radioiodination of trastuzumab was carried out by chloramine-T method, purified by using PD-10 column, and characterized by size exclusion high-performance liquid chromatography on a gel column. In vitro studies were carried out in HER2+ cells to determine the specificity of the radioimmunoconjugate...
November 4, 2016: Journal of Labelled Compounds & Radiopharmaceuticals
https://www.readbyqxmd.com/read/27798787/initial-experience-with-tositumomab-and-i-131-labeled-tositumomab-for-treatment-of-relapsed-refractory-hodgkin-lymphoma
#5
Heather Jacene, John Crandall, Yvette L Kasamon, Richard F Ambinder, Steven Piantadosi, Donna Serena, Wayne Kasecamp, Richard L Wahl
PURPOSE: To determine the maximum tolerated dose (MTD) of [(131)I]tositumomab in patients with refractory/recurrent Hodgkin lymphoma (HL) and to preliminarily determine if [(131)I]tositumomab has activity against HL and if positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]DG) performed 6 weeks post-therapy predicted 12-week response. PROCEDURES: Separate dose-finding studies were performed for patients with and without prior transplant...
October 31, 2016: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/27774839/differences-in-brain-glucose-metabolism-during-preparation-for-131-i-ablation-in-thyroid-cancer-patients-thyroid-hormone-withdrawal-versus-recombinant-human-thyrotropin
#6
Hyeonseok S Jeong, Eun Kyoung Choi, In-Uk Song, Yong-An Chung, Jong-Sik Park, Jin Kyoung Oh
BACKGROUND: In preparation for (131)I ablation, temporary withdrawal of thyroid hormone is commonly used in patients with thyroid cancer after total thyroidectomy. The current study aimed to investigate brain glucose metabolism and its relationships with mood or cognitive function in these patients using (18)F-fluoro-2-deoxyglucose positron emission tomography ((18)F-FDG-PET). METHOD: A total of 40 consecutive adult patients with thyroid carcinoma who had undergone total thyroidectomy were recruited for this cross-sectional study...
November 28, 2016: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/27727663/single-fixed-high-dose-radio-iodine-i-131-therapy-in-hyperthyroidism-a-retrospective-study
#7
Raja N Mahesh, Pranay R Korpole, Ganesh Shetty, Handrashekar U Kudru, Shivashankara K Nagiri
No abstract text is available yet for this article.
January 2016: Journal of the Association of Physicians of India
https://www.readbyqxmd.com/read/27726016/adjuvant-post-operative-i-131-therapy-in-differentiated-thyroid-carcinoma-are-the-2015-ata-guidelines-an-exact-science-or-a-dark-art
#8
Frederik A Verburg, Markus Luster, Luca Giovanella
No abstract text is available yet for this article.
October 10, 2016: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/27703298/management-of-the-patient-with-aggressive-and-resistant-papillary-thyroid-carcinoma
#9
Rame Miftari, Valdete Topçiu, Adem Nura, Valdete Haxhibeqiri
PURPOSE: Papillary carcinoma is the most frequent type of thyroid cancer and was considered the most benign of all thyroid carcinomas, with a low risk of distant metastases. However, there are some variants of papillary thyroid carcinoma that have affinity to spread in many organs, such as: lymph nodes, lungs and bones. AIM: The aim of this study was presentation of a case with papillary carcinoma of the thyroid gland, very persistent and resistant in treatment with I 131...
July 27, 2016: Medical Archives
https://www.readbyqxmd.com/read/27651737/gastrointestinal-side-effects-of-the-radioiodine-therapy-for-the-patients-with-differentiated-thyroid-carcinoma-two-days-after-prescription
#10
Mehran Pashnehsaz, Abbas Takavar, Sina Izadyar, Seyed Salman Zakariaee, Mahmoud Mahmoudi, Reza Paydar, Parham Geramifar
Iodine-131 (I-131) therapy is one of the conventional approaches in the treatment of patients with differentiated thyroid carcinoma (DTC). The radioiodine agents also accumulate in the other organs that cause pain and damage to the patients. Radioiodine therapy is associated with various gastrointestinal (GI) toxicities. In this study, GI side effects of the radioiodine therapy were investigated. GI toxicities of the radioiodine therapy were studied in 137 patients with histologically proven DTC in Jun-Nov 2014...
September 2016: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/27651699/cervical-cord-compression-as-initial-presentation-of-papillary-thyroid-carcinoma-a-case-report
#11
Veda Padma Priya Selvakumar, Ashish Goel, Kapil Kumar
Cervical cord compression secondary to extension of a long standing papillary thyroid carcinoma as well as multiple cases of distal cord compression from occult follicular thyroid carcinoma have been reported. But cervical cord compression from Papillary Thyroid Carcinoma has not been reported so far. Forty eight year old lady presented with progressive quadriparesis of 2 months duration. MRI of the cervical spine showed destructive lesion with soft tissue component in vertebral bodies and posterior elements of C4-C6 vertebrae with cord compression along with a large thyroid mass extending to retrosternal region likely malignant...
September 2016: Indian Journal of Surgical Oncology
https://www.readbyqxmd.com/read/27609732/a-review-of-treatment-options-for-graves-disease-why-total-thyroidectomy-is-a-viable-option-in-selected-patients
#12
Vinuta Mohan, Robert Lind
Graves' disease is the most common cause of hyperthyroidism. If left untreated, patients may have multiple systemic complications such as cardiac, reproductive, and skeletal disease. Thionamides, such as methimazole and propylthiouracil, and I(131) iodine ablation are the most commonly prescribed treatment for Graves' disease. Total thyroidectomy is often overlooked for treatment and is usually only offered if the other options have failed. In our case, we discuss a patient who was admitted to our medical center with symptomatic hyperthyroidism secondary to long-standing Graves' disease...
2016: Journal of Community Hospital Internal Medicine Perspectives
https://www.readbyqxmd.com/read/27568214/radiopharmaceuticals-in-acute-porphyria
#13
Nanno Schreuder, Ilahä Mamedova, Frank G A Jansman
PURPOSE: The acute porphyrias are a group of rare metabolic disorders of the heme biosynthetic pathway. Carriers of the acute porphyria gene are prone to potentially fatal acute attacks, which can be precipitated by drug exposure. It is therefore important to know whether a drug is safe for carriers of the acute porphyria gene. In this study, radiopharmaceuticals were assessed on their porphyrogenicity (ie, the potential of a drug to induce an attack). METHODS: The assessment was conducted by classifying the drugs according to the Thunell model...
August 24, 2016: Clinical Therapeutics
https://www.readbyqxmd.com/read/27555655/measurement-of-the-dose-to-the-family-members-taking-care-of-thyroid-cancer-patients-undergoing-i-131-therapy-in-nuclear-medicine-using-tld-100
#14
M Zehtabian, N Dehghan, M Danaei Ghazanfarkhani, M Haghighatafshar, S Sina
The family members or friends of the patients undergoing treatment using radioiodine in nuclear medicine are inevitably exposed to ionization radiation. The purpose of this study is measurement of the dose received by the people taking care of the thyroid cancer patients treated by (131)I. For this purpose, the dose amounts received by 29 people accompanying patients were measured using thermoluminescence dosimeters. A badge containing three TLD-100 chips was given to each caregiver. The people were asked to wear the badges for 24 days, when they are taking care of the patients...
August 22, 2016: Radiation Protection Dosimetry
https://www.readbyqxmd.com/read/27547058/second-malignancies-in-patients-with-differentiated-thyroid-carcinoma-treated-with-low-and-medium-activities-of-radioactive-i-131
#15
Doina Piciu, Claudiu Pestean, Elena Barbus, Maria Iulia Larg, Andra Piciu
BACKGROUND AND AIM: This study aimed at determining whether there is a risk regarding the development of second primary malignancies after patient exposure to the low and medium radioiodine activity used during the treatment of differentiated thyroid cancers (DTC). METHODS: Second primary malignancies that occurred after DTC were detected in 1,990 patients treated between 1970 and 2003. The mean long-term follow-up period was 182 months. RESULTS: Radioiodine I-131was administrated at a mean dose of 63...
2016: Clujul Medical (1957)
https://www.readbyqxmd.com/read/27529884/effectiveness-of-radioiodine-treatment-for-toxic-nodular-goiter
#16
Hatice Şakı, Arzu Cengiz, Yakup Yürekli
OBJECTIVE: The aim of this retrospective study is to evaluate the treatment outcomes in patients with toxic nodular goiter (TNG) that received radioiodine treatment (RAIT) and to determine the influence of age, gender, nodule size, I-131 dose, underlying etiology and antithyroid drugs on the outcomes of RAIT. METHODS: Two hundred thirty three patients (mean 64±10 years old) with TNG that received RAIT were included in the study. Treatment success was analyzed according to demographic (age and gender) and clinical data (thyroid function tests before and after RAIT, thyroid sonography and scintigraphy, I-131 dose, antithyroid drugs)...
October 5, 2015: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/27529883/long-term-results-of-fixed-high-dose-i-131-treatment-for-toxic-nodular-goiter-higher-euthyroidism-rates-in-geriatric-patients
#17
Gül Ege Aktaş, Halil Turgut Turoğlu, Tanju Yusuf Erdil, Sabahat İnanır, Fuat Dede
OBJECTIVE: Geriatric patient population has special importance due to particular challenges. In addition to the increase in incidence of toxic nodular goiter (TNG) with age, it has a high incidence in the regions of low-medium iodine intake such as in our country. The aim of this study was to evaluate the overall outcome of high fixed dose radioiodine (RAI) therapy, and investigate the particular differences in the geriatric patient population. METHODS: One hundred and three TNG patients treated with high dose I-131 (370-740 MBq) were retrospectively reviewed...
October 5, 2015: Molecular Imaging and Radionuclide Therapy
https://www.readbyqxmd.com/read/27459351/prediction-of-radioactive-iodine-remnant-ablation-failure-in-patients-with-differentiated-thyroid-cancer-a-cohort-study-of-740-patients
#18
Marin Prpic, Davor Kust, Ivan Kruljac, Lora Stanka Kirigin, Tomislav Jukic, Nina Dabelic, Ante Bolanca, Zvonko Kusic
BACKGROUND: The purpose of this study was to detect parameters that could serve as predictors of radioactive iodine (I-131) ablation failure in patients with low-risk and intermediate-risk differentiated thyroid carcinoma (DTC). METHODS: Our cohort study included 740 patients with DTC who received postoperative I-131 remnant ablation. Anthropometric, biochemical, and pathohistological parameters were analyzed and correlated with ablation outcome using multivariable logistic regression models...
July 26, 2016: Head & Neck
https://www.readbyqxmd.com/read/27445291/design-and-fabrication-of-kidney-phantoms-for-internal-radiation-dosimetry-using-3d-printing-technology
#19
Johannes Tran-Gia, Susanne Schlögl, Michael Lassmann
: Currently, the validation of multimodal quantitative imaging and absorbed dose measurements is impeded by the lack of suitable, commercially available anthropomorphic phantoms of variable sizes and shapes. To demonstrate the potential of 3-dimensional (3D) printing techniques for quantitative SPECT/CT imaging, a set of kidney dosimetry phantoms and their spherical counterparts was designed and manufactured with a fused-deposition-modeling 3D printer. Nuclide-dependent SPECT/CT calibration factors were determined to assess the accuracy of quantitative imaging for internal renal dosimetry...
December 2016: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/27434486/synthesis-and-in-vivo-evaluation-of-ortho-124-i-iodohippurate-for-pet-renography-in-healthy-rats
#20
Gopal Pathuri, Andria F Hedrick, Vibhudutta Awasthi, Benjamin D Cowley, Hariprasad Gali
Ortho-[(131)I]iodohippurate [(131)I]OIH (marketed as Hippuran I 131), a gold standard for radionuclide renography, and [(123)I]OIH were in clinical use for decades. Here we radiolabeled OIH with (124)I (a positron emitter) to combine the desirable biological properties of OIH and to enable the use of positron emission tomography (PET) for renography. [(124)I]OIH was synthesized with a slight modification to a previously reported method for the kit preparation of [(123)I]OIH based on the Cu(II) catalyzed isotope-exchange reaction...
September 2016: Applied Radiation and Isotopes
keyword
keyword
12019
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"